### Study Identification

- **Unique Protocol ID:** 2019-04-066
- **Brief Title:** Effects and Prognostic Factors of Intensive Pulse Light Treatment for Meibomian Gland Dysfunction
- **Official Title:** Effects and Prognostic Factors of Intensive Pulse Light Treatment for Meibomian Gland Dysfunction
- **Secondary IDs:**

### Study Status

- **Record Verification:** June 2019
- **Overall Status:** Active, not recruiting
- **Study Start:** April 18, 2019 [Actual]
- **Primary Completion:** June 18, 2019 [Anticipated]
- **Study Completion:** July 18, 2019 [Anticipated]

### Sponsor/Collaborators

- **Sponsor:** Samsung Medical Center
- **Responsible Party:** Principal Investigator
  - Investigator: tae-young chung [tychung]
  - Official Title: Professor
  - Affiliation: Samsung Medical Center
- **Collaborators:**

### Oversight

- **U.S. FDA-regulated Drug:** No
- **U.S. FDA-regulated Device:** No
- **U.S. FDA IND/IDE:** No
- **Human Subjects Review:** Board Status: Approved
  - Approval Number: SMC 2019-04-066
  - Board Name: Institutional Review Board of Samsung Medical Center
  - Board Affiliation: Samsung Medical Center, Seoul, Korea
  - Phone: 82-2-3410-2980
  - Email: hj0503.lee@samsung.com
  - Address:
**Study Description**

**Brief Summary:** The investigators are going to investigate the comparative efficacy of intense pulsed light therapy alone with that of intense pulsed light plus meibomian gland expression for meibomian gland dysfunction.

**Detailed Description:** Enrolled patients are going to be randomly assigned to two groups. All of the patients will undergo four treatment sessions in total, which are two weeks apart. Group 1 will undergo two sessions of intense pulsed light therapy with meibomian gland expression, as well as two sessions of intense pulsed light alone. Group 2 will receive two sessions of intense pulsed light therapy alone, and two sessions of intense pulsed light therapy with meibomian gland expression. The following parameters will be measured at baseline, 2 weeks after the second treatment session, and 2 weeks after the fourth treatment session: tearfilm break-up time, Oxford grade for corneal staining, meibomian gland expressibility, meibum quality, and ocular surface disease index.

**Conditions**

Conditions: Meibomian Gland Dysfunction

Keywords:

**Study Design**

**Study Type:** Interventional

**Primary Purpose:** Treatment

**Study Phase:** N/A

**Interventional Study Model:** Crossover Assignment

**Number of Arms:** 2

- **Masking:** Single (Outcomes Assessor)
- **Allocation:** Randomized
- **Enrollment:** 80 [Anticipated]

**Arms and Interventions**

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Comparator: Group 1</td>
<td>Device: Intense Pulsed Light (IPL)</td>
</tr>
<tr>
<td></td>
<td>IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm² to 13J/cm² according to Fitzpatrick Skin Type Grading.</td>
</tr>
</tbody>
</table>
Arms

Assignments Interventions

Other Names:
• Meibomian gland expression

Active Comparator: Group 2
Device: Intense Pulsed Light (IPL)
IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm² to 13J/cm² according to Fitzpatrick Skin Type Grading.

Other Names:
• Meibomian gland expression

Outcome Measures

Primary Outcome Measure:
1. Change from baseline tearfilm break-up time at 2 weeks after the last treatment session
   [Time Frame: Baseline and 2 weeks after the last treatment session]
2. Change from baseline Oxford grade for corneal staining at 2 weeks after the last treatment session
   Oxford grade for staining was assessed on a scale of 0 to 5. It was scaled according to the degree of corneal staining as follow: 0 (absent), 1 (minimal), 2 (mild), 3 (moderate), 4 (marked), and 5 (severe)
   [Time Frame: Baseline and 2 weeks after the last treatment session]
3. Change from baseline meibomian gland expressibility score at 2 weeks after the last treatment session
   The meibomian gland expressibility was assessed on a scale of 0 to 3 in five glands on the central lower lid. It was scaled according to the number of glands expressible, as follows: 0 (all glands), 1 (three to four glands), 2 (one to two glands) and 3 (no glands)
   [Time Frame: Baseline and 2 weeks after the last treatment session]
4. Change from baseline meibum quality score at 2 weeks after the last treatment session
   The meibum quality score were divided into the following four degrees: 0 (clear), 1 (cloudy), 2 (granular), and 3 (toothpaste)
   [Time Frame: Baseline and 2 weeks after the last treatment session]
5. Change from baseline ocular surface disease index at 2 weeks after the last treatment session
   The ocular surface diseases index score range from 0 to 100 based on the result of standardized ocular surface disease index questionnaire. Higher value represent worse subjective symptom.
   [Time Frame: Baseline and 2 weeks after the last treatment session]

Eligibility

Minimum Age:
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria: Inclusion Criteria:
- Clinical diagnosis of meibomian gland dysfunction

Exclusion Criteria:
- Medical conditions in which IPL is contraindicated (pregnancy, breastfeeding, lupus, and any major uncontrolled health problem).
- Contact lens wearer
- Previous ocular surgery
- Previous thermal treatment for dry eye disease (e.g. LipiFlow)

Contacts/Locations

Central Contact Person: Tae-Young Chung, M.D., Ph.D.
Telephone: +82-10-9933-3563
Email: tychung@skku.edu

Central Contact Backup:

Study Officials:

Locations: South Korea
Samsung Medical Center
Seoul, South Korea
Contact: Tae-Young Chung +82-10-9933-3563   tychung@skku.edu

IPDSharing

Plan to Share IPD: No

References

Citations:

Links:

Available IPD/Information: